Biodesix said this week that it has closed a structured debt financing with Capital Royalty Partners that provides the company with up to $20 million.
The funds will be used for ongoing development of Biodesix's technology platform and expansion of sales and marketing efforts in support of its VeriStrat proteomic test for guiding therapy in non-small cell lung cancer, the company said.
The deal follows the close by Biodesix in January of a $14.4 million Series E funding round.